Loading…
Chinese clinical-stage biotech developing small-molecule targeted cancer therapies, including KRAS-pathway inhibitors.
Chinese clinical-stage biotech developing small-molecule targeted cancer therapies, including KRAS-pathway inhibitors.
In one line: A Chinese Mirati Therapeutics-style KRAS/oncology biotech.
Moat: narrow (IP / patents). Patent-protected small-molecule oncology candidates targeting hard-to-drug pathways.
Headquarters: Shanghai, China · Founded: 2017 · Employees: 102
Size Genfleet Therapeutics (Shanghai) (2595.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.07B, the 581st largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$21.80 on 6 Nov 2026.
Performance Over six months the shares fell 46.5%, against -15.0% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 55.1% over the last twelve months (peer median +8.2%); the operating margin is -456.9% (peer median 8.1%).
Valuation It trades at 68.9× enterprise value to sales against a peer median of 3.2× (most expensive of 19).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$93.9M | HK$141M | HK$114M | HK$81.5M | HK$122M |
| Revenue growth | — | +24% | +39% | -33% | — |
| Gross profit | HK$28.7M | HK$80.1M | HK$76.2M | HK$60.8M | HK$88.2M |
| EBITDA | -HK$419M | -HK$268M | -HK$296M | -HK$300M | -HK$284M |
| Net income | -HK$1.45B | -HK$1.95B | -HK$735M | -HK$562M | -HK$320M |
| Free cash flow | -HK$425M | -HK$150M | -HK$225M | -HK$224M | -HK$348M |
| Capital expenditure | HK$6.32M | HK$121,467 | HK$290,572 | HK$656,369 | HK$13.8M |
| Total debt | n/a | HK$113M | HK$73.8M | HK$34.9M | HK$61.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Genfleet Therapeutics (Shanghai) 2595.HK | $1.07B | -47% | -55% | -457% | 68.9× | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| InnoCare Pharma 9969.HK | $2.31B | -13% | +146% | 35% | 3.4× | 0.8% |
| Ascentage Pharma Group International 6855.HK | $1.39B | -33% | +70% | -220% | 15.5× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2595.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -32.0% | -2.3% | lowest of 21 |
| 6-month return | -46.5% | -15.0% | 3rd lowest of 20 |
| Distance from 52-week high | -58.8% | -31.3% | 2nd lowest of 21 |
| Revenue growth (TTM) | -55.1% | +8.2% | lowest of 19 |
| Operating margin | -456.9% | 8.1% | lowest of 19 |
| EV / Sales | 68.9× | 3.2× | most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | 68.9× | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 3.2× | -5.7% | +12.7% |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 3.2× | 38.6% | +20.4% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | 14.8× | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | 4.7× | 34.1% | -6.0% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 3.0× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 1.0× | -9.4% | -7.0% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 2.4× | 5.0% | +3.5% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 4.5× | 5.5% | +7.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 1.5× | 3.4% | +1.8% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 1.8× | -6.4% | -7.7% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 1.4× | n/a | n/a |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 4.3× | 8.6% | -4.5% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 4.3× | 13.9% | +4.9% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 1.2× | 1.5% | +12.1% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | 7.6× | n/a | n/a |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 1.3× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | 5.0× | 11.9% | -13.7% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 11.8× | 49.0% | +13.8% |